TLPH Quote, Financials, Valuation and Earnings

CorMedix, Inc. has a net margin of -443600% compared to Talphera, Inc.'s net margin of 49.9%. Talphera, Inc.'s return on equity of -127.04% beat CorMedix, Inc.'s return on equity of 95.25%.

Talphera, Inc. has a consensus price target of $3.25, signalling upside risk potential of 164.23%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 79.92%. Given that Talphera, Inc. has higher upside potential than CorMedix, Inc., analysts believe Talphera, Inc. is more attractive than CorMedix, Inc..

Talphera, Inc. has a beta of 0.248, which suggesting that the stock is 75.207% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.

Talphera, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Talphera, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.

Talphera, Inc. quarterly revenues are $1K, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Talphera, Inc.'s net income of -$4.4M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Talphera, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 5.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Talphera, Inc. is 1,411.10x versus 3.56x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Iovance Biotherapeutics, Inc. has a net margin of -443600% compared to Talphera, Inc.'s net margin of -135.28%. Talphera, Inc.'s return on equity of -127.04% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.

Talphera, Inc. has a consensus price target of $3.25, signalling upside risk potential of 164.23%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $8.25 which suggests that it could grow by 275%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Talphera, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Talphera, Inc..

Talphera, Inc. has a beta of 0.248, which suggesting that the stock is 75.207% less volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.288%.

Talphera, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Talphera, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Talphera, Inc. quarterly revenues are $1K, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. Talphera, Inc.'s net income of -$4.4M is higher than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, Talphera, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Talphera, Inc. is 1,411.10x versus 2.91x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Microbot Medical, Inc. has a net margin of -443600% compared to Talphera, Inc.'s net margin of --. Talphera, Inc.'s return on equity of -127.04% beat Microbot Medical, Inc.'s return on equity of -45.11%.

Talphera, Inc. has a consensus price target of $3.25, signalling upside risk potential of 164.23%. On the other hand Microbot Medical, Inc. has an analysts' consensus of $8.75 which suggests that it could grow by 269.2%. Given that Microbot Medical, Inc. has higher upside potential than Talphera, Inc., analysts believe Microbot Medical, Inc. is more attractive than Talphera, Inc..

Talphera, Inc. has a beta of 0.248, which suggesting that the stock is 75.207% less volatile than S&P 500. In comparison Microbot Medical, Inc. has a beta of 1.171, suggesting its more volatile than the S&P 500 by 17.1%.

Talphera, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Microbot Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Talphera, Inc. pays -- of its earnings as a dividend. Microbot Medical, Inc. pays out -- of its earnings as a dividend.

Talphera, Inc. quarterly revenues are $1K, which are larger than Microbot Medical, Inc. quarterly revenues of --. Talphera, Inc.'s net income of -$4.4M is lower than Microbot Medical, Inc.'s net income of -$3.6M. Notably, Talphera, Inc.'s price-to-earnings ratio is -- while Microbot Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Talphera, Inc. is 1,411.10x versus -- for Microbot Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Beyond Air, Inc. has a net margin of -443600% compared to Talphera, Inc.'s net margin of -454.24%. Talphera, Inc.'s return on equity of -127.04% beat Beyond Air, Inc.'s return on equity of -220.61%.

Talphera, Inc. has a consensus price target of $3.25, signalling upside risk potential of 164.23%. On the other hand Beyond Air, Inc. has an analysts' consensus of $10.33 which suggests that it could grow by 798.55%. Given that Beyond Air, Inc. has higher upside potential than Talphera, Inc., analysts believe Beyond Air, Inc. is more attractive than Talphera, Inc..

Talphera, Inc. has a beta of 0.248, which suggesting that the stock is 75.207% less volatile than S&P 500. In comparison Beyond Air, Inc. has a beta of 0.304, suggesting its less volatile than the S&P 500 by 69.581%.

Talphera, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Beyond Air, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Talphera, Inc. pays -- of its earnings as a dividend. Beyond Air, Inc. pays out -- of its earnings as a dividend.

Talphera, Inc. quarterly revenues are $1K, which are smaller than Beyond Air, Inc. quarterly revenues of $1.8M. Talphera, Inc.'s net income of -$4.4M is higher than Beyond Air, Inc.'s net income of -$8.3M. Notably, Talphera, Inc.'s price-to-earnings ratio is -- while Beyond Air, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Talphera, Inc. is 1,411.10x versus 5.15x for Beyond Air, Inc.. Usually stocks with elevated PS ratios are considered overvalued.